论文部分内容阅读
观测４０例慢性肺原性心脏病（肺心病）呼吸衰竭（呼衰）患者治疗前后（衰竭期和缓解期）血浆抗凝血酶Ⅲ抗原（ＡＴ－Ⅲ：Ａｇ）及纤维连接蛋白（ＦＮ）值的变化。结果表明，呼衰期（ｎ＝２２）ＡＴ－Ⅲ：Ａｇ和ＦＮ均明显降低（Ｐ＜０．０１），而缓解期（ｎ＝１８）与对照组（ｎ＝３１）比较，其变化差异无显著性。作者认为，ＡＴ－Ⅲ：Ａｇ和ＦＮ可作为临床上估计肺心病病情程度及其预后的指标；肺心病呼衰期使用抗凝剂很有必要。
Plasma anti-thrombospondin Ⅲ (AT-Ⅲ: Ag) and fibronectin (FN) levels in 40 patients with chronic pulmonary heart disease (pulmonary heart disease) respiratory failure (respiratory failure) before and after treatment (failure and remission) Value changes. The results showed that the AT-Ⅲ: Ag and FN were significantly decreased in the respiratory failure phase (n = 22) (P <0.01), while the remission (n = 18) No significant. The authors believe that, AT-Ⅲ: Ag and FN can be used as a clinical estimate of the severity of pulmonary heart disease and prognosis indicators; pulmonary heart disease use of anticoagulants is necessary.